These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 8439951

  • 1. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 2. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S.
    J Clin Oncol; 1997 Feb 01; 15(2):796-807. PubMed ID: 9053507
    [Abstract] [Full Text] [Related]

  • 3. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL.
    Cancer Res; 1993 Oct 15; 53(20):4745-9. PubMed ID: 8402652
    [Abstract] [Full Text] [Related]

  • 4. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 5. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A, Muul LM, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):206-14. PubMed ID: 3257161
    [Abstract] [Full Text] [Related]

  • 6. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 7. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1993 Sep 15; 53(18):4315-21. PubMed ID: 8364926
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG.
    J Clin Oncol; 2003 Mar 01; 21(5):884-90. PubMed ID: 12610189
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May 01; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 10. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
    Hu HM, Urba WJ, Fox BA.
    J Immunol; 1998 Sep 15; 161(6):3033-41. PubMed ID: 9743368
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
    Sun Y, Jurgovsky K, Möller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D.
    Gene Ther; 1998 Apr 15; 5(4):481-90. PubMed ID: 9614572
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE.
    Cancer Gene Ther; 1996 Apr 15; 3(1):39-47. PubMed ID: 8785710
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.
    Eur Cytokine Netw; 2000 Jun 15; 11(2):217-24. PubMed ID: 10903800
    [Abstract] [Full Text] [Related]

  • 16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 17. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 18. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA.
    J Immunother; 2002 Feb 01; 25(4):359-72. PubMed ID: 12142559
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [Abstract] [Full Text] [Related]

  • 20. Immunological effects of BCG as an adjuvant in autologous tumor vaccines.
    Li Q, Normolle DP, Sayre DM, Zeng X, Sun R, Jiang G, Redman BD, Chang AE.
    Clin Immunol; 2000 Jan 01; 94(1):64-72. PubMed ID: 10607491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.